KPLH1130
KPLH1130 is a pyruvate dehydrogenase kinase (PDK) inhibitor. KPLH1130 potently inhibits M1 macrophage polarization by reducing the expression of pro-inflammatory cytokines, decreasing the levels of M1 phenotype markers (HIF-1α, iNOS) and nitric oxide (NO) production. KPLH1130 prevents the reduction of mitochondrial oxygen consumption rate (OCR) induced by inflammatory stimuli (LPS ((HY-D1056) + IFN-γ) in various macrophage types. KPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 can be used for the study of obesity-associated metabolic disorders and other inflammatory conditions[1].
Product Specifications
CAS Number
[906669-07-6]
UNSPSC
12352005
Target
HIF/HIF Prolyl-Hydroxylase; Interleukin Related; NO Synthase; PDHK
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/kplh1130.html
Purity
99.86
Solubility
DMSO : 135 mg/mL (ultrasonic)
Smiles
OC1=CC=C(C2=NNC(N2C3=CC=C(C)C=C3)=O)C(O)=C1
Molecular Formula
C15H13N3O3
Molecular Weight
283.28
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
N, N-Diethyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) aniline
LZP (OIT3, LZP, Oncoprotein-induced transcript 3 protein, Liver-specific zona pellucida domain-containing protein) (Biotin) discontinued